What happened
Shares of Cytek Biosciences (NASDAQ:CTKB) were down 36.3% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence. The healthcare stock closed at $11.92 last week, then fell to a 52-week low of $7.46 on Friday. The cell-analysis solutions company's shares dropped sharply after the company reported first-quarter earnings after the markets closed on Tuesday. The stock is down more than 25% so far this year.
So what
Cytek, which joined the S&P 600 Index in April, saw increased losses in Q1. The company's quarterly revenue was reported as $37.1 million, up 6%, but the company lost $6.8 million compared to a $2.2 million loss in the same period a year ago.
Another reason why investors didn't react favorably to the earnings report was the company revised revenue guidance downward. Citing macroeconomic conditions, Cytek said it expects full-year revenue between $205 million and $220 million. While that still represents growth of 25% to 34% over 2022, it is down from earlier guidance of between $225 million to $235 million.
It also didn't help the stock that president and CEO Wenbin Jiang sold 20,000 shares of Cytek stock a day after the earnings report.
Now what
Cytek has steadily increased revenue, growing annual revenue by 200% over the past five years. It won't be surprising to see the stock bounce back next week, considering the 52-week low this week. However, the move to a loss in Q1, after net income of $3.7 million in Q4, was concerning. Investors will want to see progress toward profitability in the next quarter.
10 stocks we like better than Cytek Biosciences
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Cytek Biosciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of May 8, 2023
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.